



Ref. No.01/2026-Dir (MIS)
Government of Pakistan
Ministry of National Health Services Regulations & Coordination
Drug Regulatory Authority of Pakistan
Islamabad

Dated: January 06, 2026

1. The Chairman
Pakistan Pharmaceutical Manufacturers Association (PPMA).
2. The Executive Director
Pharma Bureau.
3. Pakistan Chemist & Druggist Association,
Karachi, Pakistan

Subject: Capacity Building & Technical Awareness sessions on 2-D Barcode & Serialization and Harmonised Report Writing Performa for Inspection of Pharmaceutical Units


The Drug Regulatory Authority of Pakistan (DRAP) is pleased to inform that, pursuant to the promulgation of the revised 2-D Barcode & Serialization Rules and SRO 1587 (I)/2025 dated 25 August 2025, regarding the amendment of the Drugs (Licensing, Registering and Advertising) Rules, 1976—whereby Schedule B-II has been replaced with the PIC/S Guidelines. The matter of implementation of the 2-D barcode and serialization requirements was deliberated with the pharmaceutical industry at the Office of the Honourable Federal Minister for National Health Services, Regulations & Coordination (NHS, R&C) and at DRAP Headquarter on 31st December 2025.

2. In this regard, DRAP intends to arrange capacity-building and technical awareness sessions for the pharmaceutical industry to facilitate the effective implementation of the revised rules. Details of sessions are given as follows:

Date & Time	City	Venue
7th Jan 2026, Wednesday (9:30 am to 1:00 pm)	Islamabad/Rawalpindi	Islamabad Chamber of Commerce & Industries, G-8, Islamabad
8th Jan 2026, Thursday (10:30 am to 3:00 pm)	Lahore	Lahore Chamber of Commerce and Industries
13th Jan 2026, Tuesday (10:30 am to 3:00 pm)	Karachi	Korangi Association of Trade and Industry (KATI) , Karachi

3. PPMA, Pharma Bureau and PCDA are requested to **nominate focal persons**, disseminate this information among member companies and encourage active participation of relevant technical and regulatory staff. The cooperation in this important regulatory initiative shall be highly appreciated.

4. This issues with the approval of CEO, DRAP.


Atta Ur Rahman Chaudhry
Director (MIS)

Copy to:

1. CEO, Drug Regulatory Authority of Pakistan.
2. All Additional Directors Filed Offices (with the request to coordinate with the respective associations to finalise the arrangements please and other logistic supports to DRAP Representatives)